India’s Intranasal COVID Vaccine Superior to Intramuscular Vaccine


Drbeen Medical Lectures

India’s Intra-Nasal COVID Vaccine Superior to Intramuscular Vaccine.

Vastly superior with fewer side effects. Love this vaccine. Let’s review.

BBV154 (iNCOVACC®) vs. Covaxin.

#drbeen #koolbeens #COVID

Disclaimer: This video is not intended to provide assessment, diagnosis, treatment, or medical advice; it also does not constitute provision of healthcare services. The content provided in this video is for informational and educational purposes only. Please consult with a physician or healthcare professional regarding any medical or mental health related diagnosis or treatment. No information in this video should ever be considered as a substitute for advice from a healthcare professional.

References Immunogenicity and Tolerability of BBV154 (iNCOVACC®), an Intranasal SARS-CoV-2 Vaccine, Compared with Intramuscular Covaxin® in Healthy Adults: A Randomised, Open-Label, Phase 3 Clinical Trial by Chandramani Singh, Savita Verma, Prabhakar Reddy, Michael S. Diamond, David T. Curiel, Chintan Patel, Manish Kumar Jain, Sagar Vivek Redkar, Amit Suresh Bhate, Vivek Gundappa, Rambabu Konatham, Leelabati Toppo, Aniket Chandrakant Joshi, Jitendra Singh Kushwah, Ajit Pratap Singh, Shilpa Gaidhane, Krishna Mohan Vadrevu, BBV154 Study Group :: SSRN…